Biologics are among the most expensive pharmaceuticals but have begun to lose their
exclusivity rights over the past 15 years, offering the possibility for biosimilar competition …

Biosimilars represent a novel category in the world of follow-up medicinal products with the
requirement that they are highly similar but not identical to an approved originator biologic …

Abstract Market signals such as:(1) the limited number of biosimilars in the development
pipeline,(2) the focus of biosimilar development on high-profit therapeutic areas only, and …

The globally increasing prevalence of chronic inflammatory skin diseases has substantial
costs. Biologicals have become available as therapeutic options, but are encumbered with …

Drug budget and prescription control measures are implemented regionally in Germany,
meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region. We …

Objectives This study aimed to aid decision makers by analyzing the impact of introducing
biosimilar prescription targets on physician prescribing behavior in the prescription of …

Introduction While biosimilar medicines can contribute to the sustainability of healthcare
systems, their utilization rate varies across European countries. This study aims to identify …

Abstract In South Africa, diabetes is a serious problem where 1 in 9 adults has diabetes,
making it the country with the highest diabetes prevalence on the African continent. Even …

Cost‐control interventions that target physicians' clinical discretion are common in
healthcare, but evidence on their efficacy is scarce; in particular for" soft" policies when …

The incremental cost-effectiveness ratio (ICER) compares the change in cost of a new
treatment with the change in effect of the new treatment, known as the relative effectiveness …